Specifically, with the growing indications for RSPO gene fusions/upregulation and a concomitant oncogenic role in several cancer types, RSPOs have emerged as promising candidate targets for therapeutic intervention and inherently as potential biomarkers predicting therapy responsiveness. The gene discussed is RSPO1; the disease is cancer.